Michael Pisetsky Sells 3,128 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,128 shares of the company’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $14.25, for a total transaction of $44,574.00. Following the completion of the transaction, the senior vice president owned 255,224 shares of the company’s stock, valued at approximately $3,636,942. The trade was a 1.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

SiBone Stock Performance

SIBN opened at $15.33 on Wednesday. The firm has a market cap of $661.34 million, a P/E ratio of -27.37 and a beta of 0.83. SiBone has a 1-year low of $11.70 and a 1-year high of $20.05. The company has a 50 day simple moving average of $15.65 and a two-hundred day simple moving average of $16.27. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.38 and a quick ratio of 7.00.

SiBone (NASDAQ:SIBN) last issued its earnings results on Monday, August 4th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. SiBone had a negative net margin of 12.83% and a negative return on equity of 14.20%. The firm had revenue of $48.63 million during the quarter, compared to analyst estimates of $48.12 million. SiBone has set its FY 2025 guidance at EPS. Equities analysts forecast that SiBone will post -0.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SiBone

Several institutional investors have recently bought and sold shares of the business. American Century Companies Inc. lifted its position in SiBone by 11.1% during the first quarter. American Century Companies Inc. now owns 2,642,322 shares of the company’s stock valued at $37,072,000 after purchasing an additional 264,254 shares during the last quarter. Vanguard Group Inc. lifted its position in SiBone by 1.5% during the first quarter. Vanguard Group Inc. now owns 2,444,159 shares of the company’s stock valued at $34,292,000 after purchasing an additional 35,349 shares during the last quarter. First Light Asset Management LLC lifted its position in SiBone by 8.6% during the second quarter. First Light Asset Management LLC now owns 1,751,001 shares of the company’s stock valued at $32,954,000 after purchasing an additional 138,593 shares during the last quarter. Nuveen LLC bought a new position in SiBone during the first quarter valued at $18,605,000. Finally, Victory Capital Management Inc. lifted its position in SiBone by 55.0% during the first quarter. Victory Capital Management Inc. now owns 631,568 shares of the company’s stock valued at $8,861,000 after purchasing an additional 224,190 shares during the last quarter. Institutional investors own 98.11% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald set a $25.00 target price on shares of SiBone and gave the stock an “overweight” rating in a research report on Monday, August 11th. Weiss Ratings restated a “sell (d-)” rating on shares of SiBone in a research report on Saturday, September 27th. Finally, Wall Street Zen lowered shares of SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $23.67.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.